Gabapentinoids and Risk of Hip Fracture

Gabapentinoids and Risk of Hip Fracture

A recent study showed that gabapentinoid use was associated with an increased risk of hip fractures, especially in patients who were frail or had chronic kidney disease. 

This study, conducted in Victoria, Australia, analyzed 28,293 hip fracture cases, in order to investigate how gabapentinoid use (pregabalin and gabapentin) impacted hip fracture risk, focusing on age, frailty, and chronic kidney disease (CKD). The study used a case-case-time-control analysis, comparing medication exposure within patients during pre-fracture periods while controlling for confounders like age and baseline health.

Researchers found that gabapentinoids were linked to a 30% increased hip fracture risk after adjusting for concurrent medications and time trends. The risk was higher among frail individuals (1.75 times) and those with CKD (2.41 times). 

Researchers emphasized that frailty and CKD are significant risk factors for adverse drug events, such as falls and fractures, tied to gabapentinoids’ side effects like dizziness and gait instability. These findings align with the medications’ known central nervous system effects and highlight that frailty exacerbates such risks.

According to the authors: ‘Our findings suggest a potential utility of frailty risk scores as a risk stratification tool and the importance of assessing risks of patients individually before prescribing gabapentinoids. Further studies examining the risk of hip fractures associated with different dosages of gabapentinoids among patients with different degrees of kidney impairment or dialysis status are needed.’

Read the article here!

Join the FFN

To help make the FFN vision a reality in your country, join the FFN – for free – today
Join FFN Today